At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
AZD2516, 5 mg +3 moredrug
Likely dose
AZD2516, 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Placebo-controlled, Two-centre, Phase IIa Pharmacodynamic Cross-over Study to Assess the Effect of AZD2516 on the Total Number of Reflux Episodes in Healthy Male Volunteers
In Brief
A Phase 2 clinical trial evaluating AZD2516, 5 mg, AZD2516, 16 mg, and 2 other interventions for Reflux. Completed, enrolled 20 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to investigate the pharmacodynamic effect of AZD2516 in healthy male subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReflux
CountriesBelgium, Netherlands
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJul 2010
Primary CompletionSep 2010
TodayJul 2026
First PostedJul 1, 2010
Enrollment StartMay 1, 2010
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.0 years ago
Interventions
AZD2516, 5 mgdrug
Capsule, oral
AZD2516, 16 mgdrug
Capsule, oral
AZD2516, 40 mgdrug
Capsule, oral
Placebodrug
Capsule, oral